Costs associated with the management of overactive bladder and related comorbidities

Pharmacotherapy

Volumn 25, Issue 4, 2005, Pages 511-519

  Darkow, Theodore ^a   Fontes, Christina L ^a   Williamson, Todd E ^b   Lew, Kim H ^c  

^a Prescription Solutions   (United States)

^b Health Economics   (United States)

^c Prescription Solutions   (United States)

Author keywords

Clinical impact; Economic impact; OAB; Overactive bladder; Overactive bladder related comorbidities

Indexed keywords

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; FALLING; FEMALE; FRACTURE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OVERACTIVE BLADDER; SKIN INFECTION; URINARY TRACT INFECTION; VULVOVAGINITIS;

AGED; COHORT STUDIES; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; RETROSPECTIVE STUDIES; URINARY INCONTINENCE;

EID: 16344366887     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.4.511.61033     Document Type: Article

References (30)

1. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60(suppl 5A):7-12.
2. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-50.
3. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50(suppl 6A):100-7.
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
5. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(suppl):S574-9.
6. National Committee on Quality Assurance (NCQA). NCQA releases HEDIS 2004, 10 new measures address public health service issues. Available from http://www.ncqa.org/communications/news/hedis2004.htm. Accessed September 23, 2003.
7. Milsom I, Stewart W Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000;6(suppl):S565-73.
8. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 2001;87:760-6.
9. Wyndaele JJ. The overactive bladder. BJU Int 2001;88:135-40.
10. Thom D. Variations in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998;46:473-80.
11. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-8.
12. National Institutes of Health. Disease-specific estimates of direct and indirect costs of illness and NIH report. Bethesda: U.S. Public Health Services, 1997.
13. Zhou Z, Jensen GA. Insurance claim costs for overactive bladder disorder. Drug Benefit Trends 2001;13:45-8, 53-8.
14. Yu-Isenberg KS, Fontes CL, Wan GJ, Geissler EC, Harada AS. Acute and continuation treatment adequacy with venlafaxine extended release compared with fluoxetine. Pharmacotherapy 2004;24:33-40.
15. Stockl K, Vanderplas AM, Nicklasson L. A comparison of costs for four oral antidiabetic regimens within a managed care population. Manag Care Interface 2003;16:31-6.
16. Chen K, White TJ, Juzba M, Chang E. Oral isotretinoin: an analysis of its utilization in a managed care organization. J Manag Care Pharm 2002;8:272-7.
17. White TJ, Chang E, Leslie S, et al. Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. J Manag Care Pharm 2002;8:186-91.
18. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-7.
19. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
20. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a U.S. consensus panel of experts. Arch Intern Med 2003;163:2716-24.
21. Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care 2002;8(suppl):S598-607.
22. Nygaard I, Turvey C, Burns TL, Crischilles E, Wallace R. Urinary incontinence and depression in middle-aged United States women. Obstet Gynecol 2003;101:149-56.
23. Finley PR, Rens HR, Pont JT, et al. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health-Syst Pharm 2002;59:1518-26.
24. White TJ, Vanderplas A, Ory C, Dezii CM, Chang E. The economic impact of patient adherence with antidepressant therapy within a managed care organization. Dis Manag Health Outcomes 2003;11:817-22.
25. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002;8(suppl):S608-15.
26. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
27. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002;18:177-84.
28. McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001;7:S62-75.
29. Ouslander JG, Shih YT, Malone-Lee J, Luber K. Overactive bladder: special considerations in the geriatric population. Am J Manag Care 2000;6(suppl):S599-606.
30. Abrams P, Larsson G, Chapple C, Wein AJ. Factors involved in the success of antimuscarinic treatment. BJU Int 1999;83(suppl 2):42-7.